1 not yet recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Not yet recruiting 1 |
Follow JS207: new trials by email Literature Review of JS207 trials Research Report on JS207
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer JS207, JS007, Toripalimab - Hepatocellular Carcinoma | Phase 3 | Not yet recruiting | Shanghai Junshi Bioscience Co., Ltd. | 560 | 2026-10-08 | 2026-09-16 |
Shanghai Junshi Bioscience Co., Ltd. (1)
China (1)
Jia Fan, Ph.D. (1)